Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A user shared their positive experience with scalp micropigmentation (SMP) to cover hair thinning and a scar, choosing it over hair transplants due to its non-invasive nature and realistic results. They recommend SMP for those struggling with hair loss, emphasizing the importance of finding a trusted artist.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

A 25-year-old male experienced hair loss after taking breaks from oral dutasteride and minoxidil, leading to concerns about losing progress. He is advised to remain consistent with his current regimen and avoid adding spironolactone.

The user Consistent-Gene1334 shared their positive results in regrowing hair by using topical minoxidil and oral finasteride. Other users in the conversation praised the results and discussed the effectiveness of these treatments for diffuse thinning.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.

The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.

Using finasteride before a hair transplant can prevent further hair loss and make the transplant look more natural. Patients should continue using finasteride until hair cloning becomes available.

A user experienced severe hair loss after taking testosterone, despite using treatments like Dutasteride, RU58841, and Minoxidil. The user regrets taking testosterone, as it seems to have permanently increased sensitivity to DHT, accelerating hair loss.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.

A 19-year-old male with a family history of balding is using finasteride to thicken his hair and is considering whether to add minoxidil. Users suggest continuing finasteride for several months before deciding on minoxidil.

The conversation discusses whether to take oral minoxidil in a split dose or a single dose at night. Users suggest that taking a single 10mg dose at night is simpler, while splitting may help minimize side effects.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 32-year-old male started using a topical spray containing 0.01% finasteride and 6% minoxidil to combat hereditary male pattern baldness. He reports no side effects and is optimistic about potential hair regrowth.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

OP experienced hair improvement using NMN and quercetin after stopping finasteride, but later resumed finasteride due to shedding. They believe NMN and quercetin still help with hair loss.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

User stopped micro needling and lost hair density. Recommends consistency in treatments and not stopping micro needling even if painful.

OP mixed RU58841 with minoxidil and noticed undissolved particles. They are seeking advice on whether it matters or how to fully dissolve it.

A 19-year-old experiencing hair loss tried finasteride but stopped due to potential side effects and is considering dutasteride. They also used topical minoxidil intermittently but didn't see lasting effects.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

The user is experiencing hair loss at the hairline and is using finasteride, but considering minoxidil due to lack of improvement. Replies suggest that minoxidil may be more effective for hairline maintenance, especially when used in combination with finasteride.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user is experiencing hairline thinning despite using finasteride, minoxidil (solution and foam), dermastamping, and tretinoin. They suspect minoxidil or tretinoin might be causing the issue but are unsure.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.